Calliditas Therapeutics announced the presentations of an additional efficacy analysis of Nefecon and a real-world analysis of the use of systemic glucocorticoids – SGC – in IgA nephropathy. The presented efficacy analysis of Nefecon and sparsentan showed that treatment with Nefecon for 9 months was associated with estimated glomerular filtration rate benefit compared with continuous treatment with sparsentan. Additionally, the findings of a real-world analysis of challenges associated with the use of systemic glucocorticoids demonstrate significant side effects and costs for IgAN patients treated with systemic glucocorticoids, such as Prednisone and Prednisolone.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- M&A News: Asahi Kasei Offers to Acquire Calliditas in $1.1 Billion Deal
- Calliditas Therapeutics price target lowered to $45 from $50 at H.C. Wainwright
- Calliditas Therapeutics Q1 2024 Financial Surge
- Calliditas Therapeutics price target raised to $58 from $57 at Jefferies
- Calliditas Therapeutics Ab (CALT) Q1 Earnings Cheat Sheet
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue